CLODRONATE IN HYPERCALCEMIA AND OSTEOLYTIC BONE-DISEASE DUE TO BREAST-CANCER

Progressive osteolysis is a significant cause for morbidity in patient s with neoplasia affecting the skeleton. It gives rise to fractures, b one pain and hypercalcaemia. The mechanism for osteolysis is principal ly mediated by the activation of bone resorbing cells. The bisphosphon ates are specific inhibitors of osteoclast mediated bone resorption an d have been widely used in the management of osteolysis. Clodronate is one of the bisphosphonates that may be given by mouth or by parentera l injections. Both formulations lower serum calcium in the vast majori ty of affected patients due to the inhibition of bone resorption, More over, the agent also has significant effects on bone pain. There is in creasing evidence that the long-term use of clodronate decreases the i ncidence of intercurrent hypercalcaemia, bone pain and fracture and th ereby improves the quality of life of affected patients.